MetabolismNews.net

Metabolism Xagena

Phase 2b TULIP study results with CETP inhibitor, TA-8995, a drug in the field of dyslipidemia, were published in the Lancet. The peer-reviewed article is entitled Cholesterol ester transfer protein i ...


Results from ETC-1002-009, a phase 2b study evaluating the efficacy and safety of ETC-1002 ( Bempedoic acid ) compared with placebo in patients with hypercholesterolemia on stable statin therapy, were ...


Bococizumab is a humanized monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, which may be a potential therapeutic option for reducing low-density lipoprotein cholesterol ( LDL ...


A study has compared the efficacy [ low-density lipoprotein cholesterol ( LDL-C ) lowering ] and safety of Alirocumab ( Praluent ), a fully human monoclonal antibody to proprotein convertase subtilisi ...


The objective of a study was to evaluate the efficacy and safety of extended dosing with Mipomersen ( Kynamro ) in patients with familial hypercholesterolaemia taking maximally tolerated lipid-lowerin ...


One-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the phase 2 ( OSLER-1 ) and phase 3 ( OSLER-2 ) open-label extension studies of Evolocumab ( Repatha ), a ...


The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published in The New Engla ...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE ) and glomerular filtration rate ( GFR ) in patients wit ...


The purpose was to study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome ( OHS ) as compared with ...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus ( T2DM ) patients. The ABCD score, which comprise age, BMI, C-peptide level, and duration of type ...


It is unclear whether an intensive program of weight loss combined with exercise prevents the onset of knee pain among those at high risk. Researchers have examined whether an intensive lifestyle in ...


Statins are the treatment of choice for dyslipidemia, primarily lowering elevated LDL-C levels and reducing the occurrence of major cardiovascular events. In June 2011, the FDA ( Food and Drug Admin ...


Adding the drug Ezetimibe to treatment with Simvastatin lowers the risk of future cardiovascular problems, including myocardial infarction and stroke, in high-risk patients with acute coronary syndrom ...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda ( Liraglutide 3 mg ), the first once-daily human glucagon-like peptide-1 ( GLP-1 ) analogue for the t ...


It is unclear whether high-density lipoprotein ( HDL ) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of ...